

## Amendments to the Claims



The listing of claims will replace all prior versions and listings of claims in the application.

### Listing of the Claims:

Claim 1 (original): A pharmaceutical composition for parenteral administration comprising a somatostatin analogue comprising the amino acid sequence of formula I




wherein  $X_1$  is a radical of formula (a) or (b)



wherein  $R_1$  is optionally substituted phenyl,

$R_2$  is  $-\text{Z}_1-\text{CH}_2-\text{R}_1$ ,  $-\text{CH}_2-\text{CO}-\text{O}-\text{CH}_2-\text{R}_1$ ,




wherein  $Z_1$  is O or S, and

$X_2$  is an  $\alpha$ -amino acid having an aromatic residue on the  $C_\alpha$  side chain, or an amino acid unit selected from Dab, Dpr, Dpm, His, (Bzl)HyPro, thienyl-Ala, cyclohexyl-Ala and t-butyl-Ala, the residue Lys of said sequence corresponding to the residue Lys<sup>9</sup> of the native somatostatin-14

in free form, salt form, or protected form and tartaric acid.

Claim 2 (original): A composition according to claim 1 wherein the somatostatin analogue is a compound of formula II



wherein the configuration at C-2 is (R) or (S) or a mixture thereof, and

wherein R is  $\text{NR}_1\text{R}_2\text{-C}_{2-6}\text{alkylene}$  or guanidine- $\text{C}_{2-6}\text{alkylene}$ , and each of  $R_1$  and  $R_2$  independently is H or  $\text{C}_{1-4}\text{alkyl}$ ,

in free form, salt form or protected form.

Claim 3 (previously presented): A composition according to claim 1 wherein the compound of the somatostatin analogue is in aspartate di-salt form.

Claim 4 (previously presented): A composition according to claim 1 wherein the composition is adjusted to a pH of about 4 to about 4.5.

Claim 5 (original): A composition for parenteral administration buffered at a pH of about 4 to about 4.5 and comprising as active ingredient cyclo[4-(NH<sub>2</sub>-C<sub>2</sub>H<sub>4</sub>-NH-CO-O-)Pro]-Phg-DTrp-Lys-Tyr(4-Bzl)-Phe] or a pharmaceutically acceptable salt thereof.


Claim 6 (original): A composition according to claim 5 wherein the composition is buffered by an acetate/acetic acid, lactate/ lactic acid, or Glycin / HCl buffer.

Claim 7 (currently amended): Use of a pharmaceutical composition according to claim 1 for the preparation of a medicament for ~~acromegaly or cancer~~ Cushing's Disease.

Claim 8 (original): Use according to claim 6 for the preparation of a medicament for Cushing's Disease.

Claim 9: Cancel

Claim 10 (original): A compound of formula III



wherein R is NR<sub>1</sub>R<sub>2</sub>-C<sub>2-6</sub>alkylene or guanidine-C<sub>2-6</sub>alkylene, and each of R<sub>1</sub> and R<sub>2</sub> independently is H or C<sub>1-4</sub>alkyl,

in free form, in salt form or complex form, or in protected form, e.g. cyclo[{4-(NH<sub>2</sub>-C<sub>2</sub>H<sub>4</sub>-NH-CO-O-)Pro}-DPhg-DTrp-Lys-Tyr(4-Bzl)-Phe].

11. (new) A pharmaceutical composition according to Claim 1 wherein the somatostatin analogue is cyclo[{4-(NH<sub>2</sub>-C<sub>2</sub>H<sub>4</sub>-NH-CO-O-)Pro}-Phg-DTrp-Lys-Tyr(4-Bzl)-Phe] or a pharmaceutically acceptable salt thereof.

12. (new) A pharmaceutical composition according to claim 3 wherein the compound of the somatostatin analogue is cyclo[{4-(NH<sub>2</sub>-C<sub>2</sub>H<sub>4</sub>-NH-CO-O-)Pro}-Phg-DTrp-Lys-Tyr(4-Bzl)-Phe] or a pharmaceutically acceptable salt thereof.

13. (new) A method of treating Cushing's Disease comprising administering a pharmaceutical compositions according to Claim 11.

14. (new) A method of treating Cushing's Disease comprising administering a pharmaceutical compositions according to Claim 12.